Document:

EX-10.52

 Exhibit 10.52 
 **Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 JOINT DEVELOPMENT
AND SCALE-UP AGREEMENT 
 RELATED TO
CATALYSTS AND THEIR USE IN BIOBASED CHEMISTRY 
 - hereinafter “this AGREEMENT” - 
 This AGREEMENT, to be effective
as of the 15th day of April, 2012, and made and entered
into by and between 
 BioAmber Inc. of 1250 Rene Levesque West, Suite 4110, Montreal, Quebec, Canada H3B 4WB 

- hereinafter called BIOAMBER - 

and 
 Evonik Industries AG, having a
place of business at Rodenbacher Chaussee 4, Postfach 1345, D-63403 Hanau, Germany 
 - hereinafter called EVONIK - 

- BIOAMBER and EVONIK hereinafter PARTY or PARTIES - 
 WHEREAS, EVONIK inter alia is a manufacturer of catalyst products and has developed proprietary know-how, technology and expertise related to their development, scale-up, manufacture, marketing and
industrial application; and 
 WHEREAS, BIOAMBER is active in the field of biobased chemistry and has developed proprietary technology platform
which combines industrial biotechnology, an innovative purification process and chemical catalysis to convert renewable feedstocks into chemicals that are cost competitive replacements for petroleum derived chemicals; and 

WHEREAS, EVONIK and BIOAMBER have expressed a mutual interest to jointly develop improved and/or new catalysts and their use in the conversion of
biobased succinic acid into BDO/THF/GBL, with a particular view to an exclusive supply of such catalysts to BIOAMBER if successfully scaled up by EVONIK, and to possibly expand into the fields of (i) other C4 derivatives of succinic acid and of
succinic salts and (ii) C6 substrates and derivatives at a later stage. 
 NOW, THEREFORE, IT IS HEREBY AGREED BY THE PARTIES AS FOLLOWS:

  

	1	Definitions 

  

	1.1	“AFFILIATE” with respect to a PARTY means any company including joint-ventures which is directly or indirectly controlled by such PARTY (with
“control” meaning directly or indirectly owning or controlling at least fifty percent (50%) of such company’s voting stock, or possessing the power to direct or cause the direction of its management and policies), and which
agrees to be bound by the terms of this AGREEMENT as if being an original party hereto. 

  

	1.2	 “BACKGROUND IP” of a PARTY means all its secret know-how and expertise as well as all its patent applications, patents and other intellectual
property rights which such PARTY 

  
 Page 1 of 14

 *Confidential Treatment Requested 

	 	
owns or controls prior to the commencement of the PROJECT, or thereafter acquires or develops, however, independent of pursuing the PROJECT. 

 

	1.3	“BDO / THF / GBL” means butanediol / tetrahydrofurane / gamma-butyrolactone 

 

	1.4	“BIOAMBER FIELD” means the liquid phase hydrogenation of biobased succinic acid to manufacture BDO / THF / GBL. 

 

	1.5	 “CATALYST” means a DUPONT CATALYST or a 2ND GEN CATALYST, or, for the purposes of Article 7, an ALTERNATIVE CATALYST as defined in Article 7.2.

  

	1.6	“DEVELOPMENT PROGRAM” means a plan and schedule mutually agreed pursuant to Article 2.2 below and specifying the scope and nature of the work to be conducted
separately or jointly by the PARTIES, including deadlines and milestones. 

  

	1.7	“DUPONT CATALYSTS” means catalysts according to BIOAMBER’s [***] and other FORMULATIONS which BIOAMBER has licensed from DuPont and further developed
in-house, including modifications made to the DUPONT CATALYSTS or catalyst supports to optimize economics, conditions relating to catalyst recovery, regeneration and analysis of spent catalyst. 

 

	1.8	“FOREGROUND IP” means all results, improvements, developments, inventions, materials, processes and software, whether patentable or not, produced and
adequately documented in the performance of the PROJECT, including without limitation notebooks, experimental designs, models, and prototypes. “FOREGROUND IPR” means intellectual property rights related to FOREGROUND IP.

  

	1.9	“FORMULATION” means the description of a lab-scale CATALYST specifying the general type, the active components and their percentaged compositions, and other
typical specification features, as will result from the preparation of that CATALYST from a RECIPE. 

  

	1.10	 “2ND GEN CATALYSTS” means catalysts for use in the BIOAMBER FIELD that can offer better overall economics compared to the DUPONT-CATALYSTS. 

 

	1.11	“INFORMATION” of a PARTY (hereinafter the “PROVIDER”) means any and all technical and/or commercial information in tangible or non-tangible form
which is disclosed or made available by said PARTY to the other PARTY (hereinafter the “RECIPIENT”) for the purposes of this AGREEMENT; information provided hereunder by a PARTY’s affiliates, consultants or agents shall equally be
considered such PARTY’s INFORMATION. INFORMATION may include, but is not limited to, formulae, compositions, specifications, designs, ideas, software, algorithms, machine readable data, production and quality control methods, processes,
techniques, business policies or practices, and other technical and/or commercial information and data, as well as product samples. PROVIDER’s INFORMATION shall include, but shall not be limited to, its non-public BACKGROUND-IP.

  

	  	A PARTY’s INFORMATION shall also include any information obtained by the other PARTY under this AGREEMENT by visual inspection during audits, visits and/or
demonstrations in laboratories, pilot plants and/or production facilities of the first PARTY, e.g. regarding plant and equipment, and the applications and modes of operation thereof. 

 

	1.12	“RECIPE” means the lab-scale description of a process to synthesize a CATALYST, specifying raw materials and laboratory procedures to prepare the CATALYST in
the laboratory. 

  
 Page 2 of 14

 *Confidential Treatment Requested 

	1.13	“SCALE-UP” means the scale-up of a CATALYST into pilot-plant and commercial scale, starting with the CATALYST RECIPE. 

 

	1.14	“PRODUCTION PROCESS” means a pilot-plant and/or commercial scale process to manufacture a CATALYST, based on a RECIPE. 

 

	1.15	“PROJECT” means development of a new or improved process for the conversion of biobased succinic acid to BDO / THF / GBL via liquid phase hydrogenation.

  

	1.16	“THIRD PARTY” means any company or person except the PARTIES and their AFFILIATES. 

Further definitions are provided elsewhere in this AGREEMENT. 

 

	PART I	Biobased Succinic Acid to BDO / THF / GBF 

  

	2	Joint Development Collaboration 

  

	2.1	Each PARTY shall designate a development team, headed by a managing coordinator, to pursue the PROJECT. 

 

	  	The managing coordinators shall identify within their own organizations all BACKGROUND-IP which may be suitable and necessary for the purposes of the PROJECT and which
the respective PARTY, at its sole discretion, is willing and able to make available for the purposes of the PROJECT at the terms and conditions of this AGREEMENT. 

 

	  	Details as to the PROJECT objective and all necessary work to be carried out by the development teams shall be agreed by the managing coordinators in form of the
DEVELOPMENT PROGRAM. According to the progress of the PROJECT work and the FOREGROUND IP achieved, the DEVELOPMENT PROGRAM may be subject to necessary amendments from time to time as mutually agreed by the managing coordinators.

  

	2.2	Each PARTY’s managing coordinator shall organize and oversee all work relative to the PROJECT within his/her organization in accordance with the DEVELOPMENT
PROGRAM, shall report on the progress toward reaching the objective, and shall cause all necessary decisions to be made within his/her organization. 

  

	2.3	Managing coordinators shall not be authorized to agree to any changes in the objective or overall scope or direction of the PROJECT, to authorize amendments to this
AGREEMENT, or to give legally binding representations on behalf of any of the PARTIES. 

  

	2.4	In a first step, EVONIK shall look into the FORMULATIONS and RECIPES of the DUPONT CATALYSTS to identify possible improvements, shall modify the RECIPES accordingly,
and shall prepare samples for testing by BIOAMBER. Number, quality, quantity and other details pertaining to such samples shall be agreed by the managing coordinators and specified in the DEVELOPMENT PROGRAM. 

 

	2.5	 In a second step, the PARTIES shall look into (i) catalysts belonging to EVONIK and its AFFILIATES, (ii) catalysts belonging to THIRD
PARTIES, and (iii) catalysts in the public domain, to identify possible 2ND GEN CATALYSTS candidates. EVONIK shall work on the development of RECIPES and FORMULATIONS fur such 2ND GEN CATALYSTS, and shall prepare samples for testing by BIOAMBER. Number, quality, quantity and other details
pertaining to such samples shall be agreed by the managing coordinators and specified in the DEVELOPMENT PROGRAM. 

  
 Page 3 of 14

 *Confidential Treatment Requested 

	2.6	 BIOAMBER shall test the samples of modified DUPONT CATALYSTS and 2ND GEN CATALYSTS with respect to the BIOAMBER FIELD. 

 

	2.7	For the term of this AGREEMENT, however, only to the extent necessary for the performance of the PROJECT, and subject to THIRD PARTY’s rights, each PARTY grants to
the other PARTY the non-exclusive royalty-free right to use its BACKGROUND IP; the PARTIES shall duly inform each other of any such THIRD PARTY’s rights restrictions. 

 

	2.8	In the event a PARTY wishes to commission a THIRD PARTY with the performance of selected tasks according to the DEVELOPMENT PROGRAM, the PARTIES shall mutually agree on
any such possible commissioning; each PARTY shall be free to commission AFFILIATES with such tasks at its sole discretion. 

  

	2.9	The PARTIES shall endeavor to achieve FOREGROUND IP which will not infringe any THIRD PARTIES’ rights. For this purpose, patent surveys and other
freedom-to-operate analyses shall be part of the DEVELOPMENT PROGRAM. In any event, if such THIRD PARTIES’ rights come to either PARTY’s knowledge, and/or if the use of such rights deems necessary or appropriate to achieve the objective of
the PROJECT, such PARTY shall inform the other PARTY thereof, and the PARTIES shall mutually agree on the appropriate action to be taken. 

  

	3	EVONIK Scale Up 

  

	3.1	 After successful development, the PARTIES shall select one or more DUPONT CATALYST and/or 2ND GEN CATALYST for possible commercial manufacture and supply. 

 

	3.2	EVONIK shall perform the upscaling of such selected CATALYST(S) to develop a PRODUCTION PROCESS. 

 

	4	Costs 

  

	4.1	BIOAMBER shall pay for all costs incurred by EVONIK for CATALYSTS, including all samples and pilot scale quantities, which are produced for testing. All such CATALYST
related costs are pre-approved by BIOAMBER before engaging. 

  

	4.2	For the preparation and delivery of lab samples BIOAMBER and EVONIK shall periodically (e.g. semi-annually) specify a work package and budget to be borne by BIOAMBER.
For scale-up and commercial scale test production, EVONIK shall make individual offers for BIOAMBER’s approval. 

  

	4.3	Otherwise, each PARTY shall bear its own labor and other costs and expenses it incurs in context with the performance of the PROJECT. 

 

	5	Ownership Rights in BACKGROUND IP and FOREGROUND IP 

  

	5.1	Each PARTY shall retain all right, title and interest to its BACKGROUND IP. 

 

	5.2	 FOREGROUND IP which is related to the RECIPE, the FORMULATION and/or use and application of a DUPONT CATALYST shall be solely owned by, and is hereby
assigned to BIOAMBER. EVONIK shall fully disclose all such FOREGROUND IP developed by EVONIK to BIOAMBER. Subject to Article 5.10 below, BIOAMBER has, at its sole discretion, the exclusive right (at its own cost and expense but with the necessary

  
 Page 4 of 14

 *Confidential Treatment Requested 

	 	
cooperation of EVONIK), but no obligation, to apply for protection by FOREGROUND IPR related to such FOREGROUND IP. 

 

	5.3	FOREGROUND IP which is related to the RECIPE, the FORMULATION and/or use and application of a 2ND GEN CATALYST shall be solely owned by, and is hereby assigned to
BIOAMBER if such 2ND GEN CATALYST has originated from BIOAMBER, or was secured by BIOAMBER from a THIRD PARTY (by license or other arrangement). EVONIK shall fully disclose all such FOREGROUND IP developed by EVONIK to BIOAMBER. Subject to Article
5.10 below, BIOAMBER has, at its sole discretion, the exclusive right (at its own cost and expense but with the necessary cooperation of EVONIK), but no obligation, to apply for protection by FOREGROUND IPR related to such FOREGROUND IP.

  

	5.4	 FOREGROUND IP which is related to the RECIPE, the FORMULATION and/or use and application of a
2ND GEN CATALYST shall be solely owned by, and is hereby
assigned to EVONIK if such 2ND GEN CATALYST has originated
from EVONIK. BIOAMBER shall fully disclose all such FOREGROUND IP developed by BIOAMBER to EVONIK. Subject to Article 5.10 below, EVONIK has, at its sole discretion, the exclusive right (at its own cost and expense but with the necessary cooperation
of BIOAMBER), but no obligation, to apply for protection by FOREGROUND IPR related to such FOREGROUND IP. 

  

	5.5	 FOREGROUND IP which is related to the RECIPE, the FORMULATION and/or use and application of a
2ND GEN CATALYST shall be jointly and equally owned by
both PARTIES if such 2ND GEN CATALYST has originated from
the public domain. The PARTIES shall fully disclose to each other all such FOREGROUND IP developed by the PARTIES. 

  

	5.6	In case such jointly owned FOREGROUND IP (according to Article 5.5 above) may be protectable by FOREGROUND IPR, the PARTIES shall mutually agree on the world-wide joint
application for such FOREGROUND IPR (hereinafter “JOINT FOREGROUND IPR”), or to retain the said FOREGROUND IP as trade secret, e.g. if a PARTY has good reasons to believe that the patent application would lack a reasonable chance to be
granted. The PARTIES shall each have an equal share in JOINT FOREGROUND IPR, and shall each bear one-half of the external costs associated therewith; each PARTY shall bear its own internal costs it may incur in context therewith.

  

	5.7	In case a PARTY is not interested in the application, maintenance and prosecution of any JOINT FOREGROUND IPR, then the other PARTY shall be entitled to further pursue
such JOINT FOREGROUND IPR as its solely owned FOREGROUND IPR at its own cost and in its own name; the waiving PARTY shall retain a non-exclusive, royalty-free license for its and its AFFILIATES’ scientific and commercial purposes.

 The PARTIES shall come to a mutual understanding concerning how the FOREGROUND IPR maintenance fees shall be
paid. If either PARTY fails to pay its share of the fee when due then the other PARTY may pay this fee to prevent the FOREGROUND IPR from lapsing. The non-paying PARTY shall have six (6) months to reimburse the paying PARTY along with interest
and costs. Failure to do this shall be interpreted as the non-paying PARTY abandoning all its rights. The non-paying PARTY shall then become obligated to assign all its rights and interest to the paying PARTY. 

 

	5.8	In case the (alleged) infringement of any JOINT FOREGROUND IPR by any THIRD PARTY may come to the knowledge of a PARTY, such PARTY shall promptly notify the other PARTY
thereof. The PARTIES shall then mutually agree on any action to be taken in context therewith. 

 If the PARTIES
agree to jointly act against such a THIRD PARTY infringer, then any judgment awarded to the PARTIES shall be shared between the PARTIES according to the PARTIES’ share of the related cost and expense. If a PARTY waives its right in such

  
 Page 5 of 14

 *Confidential Treatment Requested 

 
joint action against such a THIRD PARTY, the other PARTY may do so at its own cost and risk; the other PARTY shall be fully entitled to any judgment awarded in context therewith. The waiving
party shall execute all declarations, proxies and other documents as are reasonably necessary or appropriate to enable the other PARTY to take such action, and shall pro forma joining such action at the acting PARTY’s cost where required
by applicable law. 
  

	5.9	FOREGROUND IP which is related to the PRODUCTION PROCESS shall be solely owned by, and is hereby assigned to EVONIK, irrespective of the source of the underlying
compositions and lab-recipes (BIOAMBER, EVONIK, licensed in, or from the public domain), and irrespective of which PARTY owns the rights to the respective of CATALYST pursuant to the foregoing. Subject to Article 5.10 below, EVONIK has, at its sole
discretion, the exclusive right (at its own cost and expense but with the necessary cooperation of BIOAMBER), but no obligation, to apply for protection by FOREGROUND IPR related to such FOREGROUND IP. There is no obligation for EVONIK to disclose
to BIOAMBER any details with respect to such FOREGROUND IP. 

  

	5.10	The PARTIES shall coordinate and harmonize their applications for FOREGROUND IPR, including without being limited to JOINT FOREGROUND IPR, pursuant this Article 5 above
to optimize the PARTIES’ chances and probabilities to obtain broad FOREGROUND IPR coverage. Without PROVIDER’s prior written consent, RECIPIENT shall not file any FOREGROUND IPR application which may disclose or may be based on or require
use of or incorporate or incorporate by reference or otherwise any of PROVIDER’s INFORMATION, including without limitation product samples or INFORMATION pertaining thereto. 

 

	5.11	Any further details in context with the above shall be agreed by the PARTIES in due time; otherwise, however, subject to the foregoing provisions, the PARTIES shall
endeavor to, and shall cause and direct its inventors and other concerned personnel (as may apply) to, cooperate and provide all reasonable assistance, however, not financially, as may be necessary in context with the assignment, application,
maintenance and prosecution of FOREGROUND IPR, as well as with action to be taken against THIRD PARTY infringers, as provided above. 

  

	5.12	In anticipation of this AGREEMENT and as mutually agreed by the PARTIES, EVONIK has, during the period from Jan 1, 2012 and the effective date hereof, prepared certain
CATALYST samples on a lab scale, and has performed certain CATALYST scale-up work. Such preparation of samples and scale-up work shall be deemed as if having been made hereunder within the scope of the PROJECT, and the results obtained shall be
deemed FOREGROUND IP, subject to all relevant terms and conditions of this AGREEMENT. 

  

	6	Commercialization of FOREGROUND IP / Rights to Use 

  

	6.1	BIOAMBER is hereby granted a non-exclusive, royalty-free, perpetual license to practice any FOREGROUND IP, including without being limited to FOREGROUND IPR related
thereto, owned by EVONIK pursuant to Article 5.4, subject to the exclusivity arrangements pursuant to Article 7 below and related thereto. There shall be no further obligations or liabilities for EVONIK with respect to such license grant.

  

	6.2	 EVONIK is hereby granted a non-exclusive, royalty-free, perpetual license to practice any FOREGROUND IP, including without being limited to FOREGROUND
IPR related thereto, owned by BIOAMBER pursuant to Article 5.2 and 5.3, subject to the exclusivity arrangements pursuant to Article 7 below and related thereto. There shall be no further obligations or liabilities for BIOAMBER with respect to such
license grant. Further, if the 

  
 Page 6 of 14

 *Confidential Treatment Requested 

	 	
results are depending on a license granted to BIOAMBER, BIOAMBER is under no obligation to grant to EVONIK a sublicense, or to otherwise arrange for a license to be granted to EVONIK, except that
BIOAMBER shall arrange for all necessary rights for EVONIK to lawfully manufacture CATALYST for BIOAMBER, BIOAMBER’s AFFILIATES and/or licensees of BIOAMBER. 

 

	6.3	Otherwise, the PARTY solely owning FOREGROUND IP, including without being limited to FOREGROUND IPR related thereto, according to Article 5 above shall have the
exclusive right to commercially use such FOREGROUND IP and FOREGROUND IPR. 

  

	6.4	With respect to jointly owned FOREGROUND IP, including without being limited to FOREGROUND IPR related thereto, the PARTIES shall equally be entitled to commercially
use such FOREGROUND IP including JOINT FOREGROUND IPR for its own purposes, without obligation to pay any compensation to the other PARTY, subject to the exclusivity arrangements pursuant to Article 7 below and related thereto.

 To the extent jointly owned FOREGROUND IP is protected by copyright(s), each PARTY shall have, within the rights
and limitations as provided elsewhere in this AGREEMENT, the right to use and/or commercialize for its own purposes any such copyrightable jointly owned FOREGROUND IP including without limitation their reproduction, modification, preparation of
derivative work, release, sale, distribution of copies, performance, display or disclosure. 
 Commercial use pursuant to the
foregoing in this Article 6.4 shall include without being limited to the manufacture, distribution, sale and use by a PARTY, and its suppliers, agents and customers (as may apply). 

 

	6.5	Each PARTY may, without notice to or consent required from the other PARTY, extend its rights under in this Article 6 above to any AFFILIATE (such extension to be
effective only so long as the AFFILIATE remains an AFFILIATE of such PARTY), provided such AFFILIATE agrees to be bound by all relevant obligations and restrictions in connection with such rights as provided in this AGREEMENT, including without
being limited to the exclusivity provisions in Article 7. 

  

	6.6	The using PARTY may grant licenses, sublicenses and/or immunities (as may apply) within the scope of its own rights to use granted to it hereinabove. However, any other
licenses under JOINT FOREGROUND IPR to THIRD PARTIES shall require the prior written consent of the other PARTY which shall not be unreasonably withheld, delayed or conditioned. 

 

	6.7	By virtue of this AGREEMENT, no rights or licenses are granted to either PARTY except as expressly stated herein. In particular, except as provided in Article 2.7
above, nothing in this AGREEMENT shall be construed as granting, or as an undertaking to subsequently grant, to a PARTY any license, right, immunity, title or interest in or to any INFORMATION including without being limited to BACKGROUND IP of the
other PARTY. 

  

	7	Exclusive Commercialization 

  

	7.1	For the duration of the PARTIES’ performance of PROJECT work hereunder, EVONIK shall not pursue independently or engage with any THIRD PARTY in a project related
to catalysts for use in the BIOAMBER FIELD. For the avoidance of doubt: This obligation will terminate as soon as the PARTIES have finally terminated their PROJECT work according to the DEVELOPMENT PROGRAM, even if this AGREEMENT has not yet
formally expired pursuant to Article 11.1. 

  

	7.2	 Subject to all relevant confidentiality obligations and other terms and conditions provided herein, BIOAMBER shall be free to pursue independently or
engage with any THIRD 

  
 Page 7 of 14

 *Confidential Treatment Requested 

	 	
PARTY development work related to the BIOAMBER FIELD or not and/or catalysts therefor, and/or to license such catalysts, (with respect to the BIOAMBER FIELD: both, “ALTERNATIVE
CATALYST”). 

 however: 

 

	7.3	BIOAMBER shall source its requirement of CATALYST (i.e. SCALE-UP and commercial supply, even if licensed in or independently developed) exclusively from EVONIK for a
period terminating fourteen (14) years from the first commercial scale delivery to BIOAMBER (“EXCLUSIVITY PERIOD”), and to give EVONIK a first right to match competing offers for the supply of CATALYST for five years after the
EXCLUSIVITY PERIOD, provided that EVONIK has successfully scaled up such CATALYST (meaning that mutually agreed milestones, price and performance targets are met). For all BDO / THF / GBL production in or destined for the European Union, the
EXCLUSIVITY PERIOD shall be initially limited to seven (7) years, and after the initial 7-year-period the PARTIES shall seek to renew for another seven (7) years, subject to European anti-trust regulations then in effect.

  

	7.4	For the duration of the EXCLUSIVITY PERIOD, EVONIK shall not itself commercially use, nor supply to any AFFILIATE or THIRD PARTY any CATALYST for commercial use in the
BIOAMBER FIELD, without BIOAMBER’s prior written consent which may be given or withheld at BIOAMBER’s sole discretion. 

  

	7.5	The EXCLUSIVITY PERIOD shall terminate prior to its regular expiration pursuant to Article 7.3, unless otherwise agreed to by the PARTIES in writing, in the event:

  

	 	(a)	that EVONIK fails to successfully perform the SCALE-UP of a CATALYST as selected by BIOAMBER according to mutually agreed milestones, price and performance targets; or

  

	 	(b)	that BIOAMBER does not wish to perform any SCALE-UP within three (3) months from successful development of a CATALYST and EVONIK’s proposal for a SCALE-UP; or

  

	 	(c)	that EVONIK has successfully performed the SCALE-UP of a CATALYST as selected by BIOAMBER, however, BIOAMBER has not purchased a commercial amount within two
(2) years from completion of the SCALE-UP; or 

  

	 	(d)	of the insolvency or bankruptcy of a PARTY. 

  

	7.6	The commercial supply of CATALYST(S) to BIOAMBER is to be governed by one or more separate agreement(s) between the PARTIES which would include price indexing, margin
protection, value sharing, the right to source catalysts from third parties if EVONIK has not the capability to fulfill BIOAMBER’s volume requirements and second look clauses (second look being BIOAMBER’s right, from time to time, to
consult THIRD PARTY catalyst suppliers to ensure that EVONIK CATALYST performance and pricing is in line with the market). A commercial master agreement covering an initial term of seven (7) years shall be duly executed by the PARTIES by
September 30, 2012 specifying all relevant details. CATALYST specification, price, quantities and delivery dates shall be defined in an addendum to the commercial master agreement at least six (6) months before the first commercial supply
of any CATALYST. If such a commercial master agreement (supply agreement) cannot be reached by the said day, the PARTIES may continue their collaboration and contract negotiations hereunder, however, each PARTY has a right to terminate this
AGREEMENT pursuant to Article 11.2(ii) at any time after such day as long as the PARTIES have not yet executed such a commercial master agreement. 

  
 Page 8 of 14

 *Confidential Treatment Requested 

 After the said 7-year initial term, the PARTIES shall in good faith negotiate a renewal of
such supply agreement. If a THIRD PARTY catalyst supplier (a “Supplier”) offers to BIOAMBER to supply CATALYST(S) at significantly better terms and conditions (a price that is at least [***] below the price offered by EVONIK shall be
deemed to constitute significant better terms and conditions) than those offered by EVONIK, and such third party CATALYST has been scaled up by the Supplier, and has been successfully tested by BIOAMBER in a pilot or semi-commercial plant for at
least five hundred (500) hours, then EVONIK will have the option to adjust the terms and conditions offered to BIOAMBER, including the pricing, in accordance with those contained in the offer from the Supplier, failing which BIOAMBER will be
entitled to source all or a certain quantity of CATALYST(S) from the Supplier, according to the terms presented to EVONIK, and the EXCLUSIVITY PERIOD as provided in Article 7.3 above will terminate. 

PART II    Prospect - Possible Extension of the Collaboration 

 

	8	Further Fields for Collaboration 

  

	8.1	EVONIK and BIOAMBER may, at a later date and on a non-exclusive basis, decide to undertake joint development of novel catalysts that can assist in chemical reactions
related to derivatives of succinic acid and succinate salts other than BDO / THF / GBL (“C4 DERIVATIVES”), and/or EVONIK may decide to optimize and scale up catalysts identified by BIOAMBER and possibly secured from THIRD PARTIES. If the
PARTIES agree to extend their collaboration to the C4 DERIVATIVES field, it is the current expectation that the arrangement would be substantially identical to the arrangement according to PART I hereinabove. 

 

	8.2	EVONIK and BIOAMBER may, at a later date and on a non-exclusive basis, decide to undertake joint development of catalysts that can assist in the conversion of certain
fermentation derived intermediates into adipic acid, HMDA, caprolactam and possibly other C6 chemicals such as hexanediol (“C6 DERIVATIVES”). More discussion on the scope of this work is required between the PARTIES. Alternatively, or
additionally, BIOAMBER may secure catalyst ideas from THIRD PARTIES that EVONIK would develop and optimize. If the PARTIES agree to extend their collaboration to the C6 DERIVATIVES field, it is the current expectation that the arrangement would
substantially identical to the arrangement according to PART I hereinabove. 

 PART III    General
Provisions 
  

	9	Confidentiality and Restricted Use 

  

	9.1	For the term of this AGREEMENT and for ten (10) years thereafter, RECIPIENT shall keep in strict confidence PROVIDER’s INFORMATION and shall not, subject to
Article 8.2 below, without the prior written consent of PROVIDER 

  

	 	a)	use any such INFORMATION for any purpose other than in context with the pursuance of the PROJECT; nor 

 

	 	b)	disclose or make available any such INFORMATION to any third party; nor 

  

	 	c)	disclose or make available any such INFORMATION to any officers, employees, consultants or other collaborators other than to those who require access to the INFORMATION
in context with the pursuance of the PROJECT, and who agree to be bound by the terms of this AGREEMENT, and then only to the extent required for this purpose; RECIPIENT shall assume full responsibility for the performance of its officers, employees,
consultants and/or other collaborators under this AGREEMENT; nor 

  
 Page 9 of 14

 *Confidential Treatment Requested 

	 	d)	make any other commercial use of any such INFORMATION, nor make any such INFORMATION the subject matter of or otherwise use it directly or indirectly in context with
any application for patent or other intellectual property rights. 

 In the event PROVIDER has in advance agreed in
writing that RECIPIENT may disclose PROVIDER’s INFORMATION to a THIRD PARTY, RECIPIENT shall assure that such THIRD PARTY shall be bound by obligations not less onerous than RECIPIENT’s obligations assumed hereunder, and RECIPIENT shall
remain liable for any unauthorized disclosure, dissemination and/or use of PROVIDER’s INFORMATION by such THIRD PARTY. 
  

	9.2	The restrictions provided in Article 9.1 above shall not apply to any INFORMATION for which RECIPIENT can prove that such INFORMATION 

 

	 	a)	at the time of disclosure hereunder was, or thereafter becomes, part of the public domain through no act or omission of RECIPIENT in breach of this AGREEMENT; or

  

	 	b)	was already in RECIPIENT’s possession at the time of disclosure hereunder, or is hereafter in good faith received by RECIPIENT from a third party without an
obligation of confidentiality and/or restrictions as to its use still in effect; or 

  

	 	c)	is hereafter independently developed by or on behalf of RECIPIENT without recourse to PROVIDER’s INFORMATION or relevant part thereof. 

Specific items of INFORMATION shall not fall within any exception merely because they are embraced by more general information falling
within any exception. Likewise, any combination of specific items of INFORMATION shall not fall within any exception merely because the specific items themselves fall within any exception, but only if the combination itself, and its principles of
operation, fall within any exception. 
  

	9.3	All INFORMATION provided hereunder shall at all times remain the property of PROVIDER. Upon PROVIDER’s written request, RECIPIENT shall (a) return to PROVIDER
all documents and electronic or other storage media received hereunder and containing INFORMATION, including without limitation all unconsumed samples, and shall (b) destroy (including without limitation deletion from electronic or other
storage media, except for backups of computer records maintained as part of the RECIPIENT’s reasonable IT policy always provided such records shall not be accessible or usable by any party unless as necessary when computer records of the
RECIPENT are otherwise lost and then provided all obligations hereunder shall apply to any access and/or use thereof) all copies, reproductions, summaries, notes, memoranda and other tangible documents to the extent containing PROVIDER’s
INFORMATION. Such request may be submitted at any time; provided, however, RECIPIENT is not obliged to keep any such documents, electronic storage media, samples etc. for more than six (6) months after expiration or termination of this
AGREEMENT to comply with such obligation to return INFORMATION. Notwithstanding the foregoing, RECIPIENT may retain one (1) copy of INFORMATION in its confidential files for documentation purposes, subject to all confidentiality and non-use
obligations contained herein. 

  

	9.4	The disclosure of any INFORMATION hereunder will not be considered a “publication” thereof for patent or copyright purposes, nor will it constitute release of
said INFORMATION into the public domain. 

  

	9.5	 With respect to a PARTY, the obligations provided in this Article 9 above shall apply, mutatis mutandis, to such FOREGROUND IP which according
to Article 5 above will be assigned to the other PARTY, as well as for the jointly owned FOREGROUND IP pursuant to Article 5 above. Where the commercialization activities by a PARTY in connection with this AGREEMENT require the disclosure of jointly
owned 

  
 Page 10 of 14

 *Confidential Treatment Requested 

	 	
FOREGROUND-IP, the PARTIES shall in good faith discuss and shall mutually agree on the terms and conditions of such disclosures. 

 

	9.6	Once this AGREEMENT is executed, the PARTIES shall jointly issue a press release describing their partnership related to catalysts in the field of biobased chemicals,
with an initial focus on BDO / THF / GBL and possible further work in the other fields if agreed to by the PARTIES. Disclosure of this agreement will be permitted if obligated by a securities exchange. In such event, the Parties will use their best
efforts to obtain confidential treatment of important terms and conditions contained in this Agreement. 

  

	10	Warranties and Liabilities 

  

	10.1	Although PROVIDER believes its INFORMATION is accurate, INFORMATION is provided strictly on an as-is basis, and RECIPIENT shall be solely responsible for its
practice or use of, or reliance on, or inability to practice or use PROVIDER’s INFORMATION. In particular, however, without limiting the generality of the foregoing, PROVIDER makes no representation, extends no warranty or condition of any
kind, express or implied, and accepts no liability, with respect to any INFORMATION provided hereunder, including but not limited to warranties of accuracy, reliability, novelty, completeness, merchantability, fitness for any particular purpose or
non-infringement of the intellectual property rights of third parties. 

  

	10.2	Each PARTY shall use commercially reasonable efforts to duly pursue its tasks under the DEVELOPMENT PROGRAM to ensure the best possible results based on the scientific
evidence, methods and techniques known at the time and in accordance with current legislation, as may apply; provided, however, that it is understood that the PROJECT is exploratory in nature and the performance of the DEVELOPMENT PROGRAM hereunder
is subject to normal experimental error, and that neither PARTY warrants that the PROJECT will be successful and/or that any FOREGROUND IP obtained hereunder will meet either PARTY’s scientific and/or commercial expectations, in whole or in
part. The failure of a PARTY to e.g. successfully perform its work according to the DEVELOPMENT PROGRAM or to meet the objectives of the PROJECT, or to successfully commercialize the PROJECT results will not constitute a breach of any representation
or warranty or other obligation under this AGREEMENT. In particular, however, without limiting the generality of the foregoing, neither PARTY makes any representation or extends any warranty or condition of any kind, express or implied, and
accepts no liability, with respect to the CATALYSTS and other FOREGROUND IP developed hereunder, including but not limited to warranties of accuracy, reliability, novelty, completeness, merchantability, fitness for any particular purpose or
non-infringement of the intellectual property rights of third parties. 

  

	10.3	Neither PARTY shall, under any circumstances, be liable to the other for indirect, incidental, special or consequential damages (including but not limited to loss of
profits, revenue, anticipated savings or business) resulting from or in any way related to this AGREEMENT, termination of this AGREEMENT or failure by either PARTY. Further, a PARTY’s liability to the other PARTY shall be restricted to intent
and gross negligence. These limitations apply regardless of whether such damages are sought based on breach of contract, negligence or any other legal theory. 

 

	10.4	The foregoing liability restrictions pursuant to Article 10.3 shall not apply with respect to any breach of confidentiality and non-use obligations pursuant to Article
9, and with respect to any unauthorized use of the other PARTY’s BACKGROUND IP and/or FOREGROUND IP, or in cases of mandatory liability. 

  
 Page 11 of 14

 *Confidential Treatment Requested 

	10.5	Warranties and liabilities with respect to a possible future CATALYST(S) supply to BIOAMBER shall be governed by the respective CATALYST supply agreement between the
PARTIES, however, it is the PARTIES understanding that EVONIK shall bear liability with respect to possible THIRD PARTY rights regarding the manufacture of the CATALYST, subject to possible licenses required to be arranged by BIOAMBER pursuant to
Article 6.2, while BIOAMBER shall bear liability with respect to the use of such CATALYST. 

  

	11	Term and Termination 

  

	11.1	This AGREEMENT shall become effective as of the date first above written and shall remain in force for a period of three (3) years. 

 

	11.2	Either PARTY may terminate this AGREEMENT 

 (i) with or without reason upon six (6) months prior written notice (by registered mail/return receipt requested or equivalent) 

(ii) effective immediately upon written notice (by registered mail/return receipt requested or equivalent) pursuant to Article 7.6.

  

	11.3	Either PARTY may terminate this AGREEMENT, effective immediately, for good cause, upon written notice (by registered mail/return receipt requested, or equivalent),
provided that the terminating PARTY has prior to such termination consulted with the other PARTY to discuss its reasons for such intended termination. 

 Good cause shall be deemed to exist, in particular: 
  

	 	•	 	 in case of only marginal progress or of a substantial delay in the pursuance of the PROJECT which is not attributable to the terminating PARTY, or in
case of other circumstances which may prevent the PARTIES from achieving the objectives of the PROJECT, 

  

	 	•	 	 if, to the reasonable judgment of the terminating PARTY, the objectives of the PROJECT can not be achieved at all, or may only be achieved upon
unexpectedly high efforts or efforts which may render the PROJECT economically unviable, 

  

	11.4	Good cause shall further be deemed to exist in case the other PARTY has committed or permitted a substantial breach of this AGREEMENT and has failed to remedy the same
within thirty (30) days after being called upon by the first PARTY to do so by written notice specifying the nature of the breach; in which case termination pursuant to this Article 11.3 shall be without prejudice to any other right or remedy
the non-defaulting PARTY may have by law or otherwise. 

  

	11.5	Rights and obligations pursuant to Article 4, 5, 6, 7 (except, for the avoidance of doubt, Article 7.1, and subject to the provisions contained in Section 7), 9,
10 and 12 herein shall survive expiration of this AGREEMENT pursuant to Article 11.1 or any extension thereof above for an indefinite period of time, unless otherwise specified therein. 

 

	11.6	Rights and obligations pursuant to Article 4, 9, 10 and 12 herein shall survive early termination of this AGREEMENT pursuant to Article 11.2, 11.3 or 11.4 above for an
indefinite period of time, unless otherwise specified therein; the same shall apply accordingly with respect to Article 5 and 6 above to the extent FOREGROUND IP has been achieved prior to such termination, except that in the event of termination
pursuant to 

 (i) Article 11.2(i) or 11.3 the terminating PARTY, or 

(ii) Article 11.4 the defaulting PARTY, 

  
 Page 12 of 14

 *Confidential Treatment Requested 

 the license rights to use the other PARTY’s FOREGROUND IP, including without being
limited to FOREGROUND IPR related thereto, shall come into effect only after five (5) years from the date of termination. 
  

	12	Miscellaneous 

  

	12.1	Should any of the provisions of this AGREEMENT become or prove to be null and void this will be without effect on the validity of this AGREEMENT as a whole. The PARTIES
will, however, endeavor to replace the void provision by a valid one which in its economic effect complies most with the void provision. The same shall apply accordingly in the event that this AGREEMENT contains any unintended omissions.

  

	12.2	Should the effect of this AGREEMENT resulting from future unforeseen events and/or by the alteration of any circumstances surrounding this AGREEMENT lead to an unjust
hardship for either PARTY which hardship does not correspond with the intentions of the PARTIES as set out in this AGREEMENT and which cannot be expected of the PARTIES in good faith, the PARTIES shall without delay enter into negotiations to see in
what way the conditions of the AGREEMENT can be made to suit the altered circumstances. 

  

	12.3	The failure of either PARTY to perform any obligation under this AGREEMENT solely by reason of causes beyond its reasonable control, including but not limited to acts
of God, natural disasters, acts, laws, regulations or rules of any government body or governmental agency, war, revolution, invasion, insurrection, riots, mob violence, sabotage or other civil disorders, strikes or other labor disputes, shall not be
deemed a breach of this AGREEMENT; provided, however, that the PARTIES shall promptly meet to determine an equitable solution to the effects of such force majeure, and provided further the PARTY so prevented from complying herewith shall continue to
take all reasonable actions within its power to comply as fully as possible herewith and to resume with the least possible delay compliance with its obligations. 

 

	12.4	No failure or delay of either PARTY in insisting upon or enforcing any of the provisions of this AGREEMENT, or in exercising any right, power, privilege or remedy
hereunder, and no partial or single exercise thereof, shall be construed or constitute a waiver or subsequent waiver of such right, power, privilege, remedy or of any other rights hereunder. 

 

	12.5	This AGREEMENT is to be governed by and construed in accordance with the substantive laws of Switzerland without giving effect to its conflict of laws rules. All
disputes arising out of or in connection with this AGREEMENT which cannot be amicably solved by the PARTIES shall be finally settled by arbitration under the Rules of Conciliation and Arbitration of the International Chamber of Commerce by three
(3) arbitrators appointed in accordance with the said Rules. The place of arbitration shall be Zurich, Switzerland. The arbitration shall be held in English. The award of the arbitration shall be final and binding upon the PARTIES, and shall be
enforceable by any court of competent jurisdiction. The PARTIES shall cooperate with each other in causing the arbitration proceedings to be held in as efficient and expeditious a manner as practicable, and the prevailing PARTY shall be entitled to
recover from the other PARTY all its costs and expenses, including without limitation reasonable attorney fees, incurred in context therewith. 

  

	12.6	In the event of a substantial breach of this AGREEMENT, the recovery of monetary damages may be an insufficient and inadequate remedy and either PARTY may,
notwithstanding the foregoing and without waiving any other rights or remedies, apply to any court of competent jurisdiction for an injunction or other equitable relief to prevent or restrain the breach of this AGREEMENT. 

  
 Page 13 of 14

 *Confidential Treatment Requested 

	12.7	This AGREEMENT shall inure to the benefit of and shall be binding upon each of the PARTIES hereto and its successors and permitted assignees, provided that any such
assignee shall agree to abide to all obligations and restrictions as provided in this AGREEMENT. Either PARTY may assign this AGREEMENT and/or its rights and obligations to an entity which acquires all or substantially all of such PARTY’s
business or assets to which this AGREEMENT pertains, whether by merger, reorganization, acquisition, sale or otherwise. Any other assignment shall be subject to the prior written consent of the other PARTY which shall not be unreasonably withheld,
delayed or conditioned. 

 Either PARTY shall at its discretion be entitled to assign its ownership and license
rights pursuant to Article 5 and 6 to any AFFILIATE or THIRD PARTY, provided such AFFILIATE or THIRD PARTY agrees to honor all grants of rights, and all obligations and restrictions arising from this AGREEMENT and associated therewith as if being an
original party to this AGREEMENT. 
  

	12.8	This AGREEMENT constitutes the entire understanding between the PARTIES hereto with respect to the subject matter hereof, and its terms, including this provision
itself, may not be changed or amended except by an instrument in writing mutually agreed to by the PARTIES. The collaboration hereunder shall not be considered work for hire, and the relationship created by this AGREEMENT shall be that of
independent contractors. Neither PARTY, by operation of this AGREEMENT, obtains the authority to bind or act as agent for the other PARTY or its employees for any purpose. 

 

					
	Hanau, this April 27, 2012	 	           Montreal, this April 16, 2012	 	 
			
	Evonik Industries AG	 	           BioAmber Inc.	 	

  

							
	/s/ Wilfried Eul	    	/s/ Ulrich Hertz	    	 /s/ Jean-François Huc
	  	 
	ppa. Dr. Wilfried Eul	    	ppa. Dr. Ulrich Hertz	    	Jean-François Huc	  	
	Senior VP	    	Head of TechTransfer	    	President & Chief Executive Officer	  	
	Catalysts Business Line	    	& Licensing	    		  	

  
 Page 14 of 14

 *Confidential Treatment RequestedEX-10.58

 Exhibit 10.58 
 **Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 TECHNOLOGY LICENSE AGREEMENT 

This Technology License Agreement (hereinafter “Agreement”) dated February 15th, 2012 (the “Effective Date”) is by and among
Sinoven Biopolymers, Inc., a corporation duly organized and existing under the laws of the State of Delaware, having its principal place of business in Malvern, Pennsylvania (hereinafter called “Sinoven”); NatureWorks LLC, a limited
liability company organized and existing under the laws of the State of Delaware, having its principal place of business in Minnetonka, Minnesota (hereinafter called “NatureWorks”); AmberWorks LLC, a limited liability company duly
organized and existing under the laws of the State of Delaware, having its principal place of business in Plymouth, Minnesota (hereinafter called “LLC”), and BioAmber, Inc. a corporation duly organized and existing under the laws of
the State of Delaware (hereinafter called “BioAmber”). 
 WITNESSETH: 

WHEREAS, NatureWorks and Sinoven have formed LLC and each own, directly or indirectly, a fifty percent (50%) interest in LLC;

 WHEREAS, in establishing LLC, NatureWorks and Sinoven, along with BioAmber, wish to enter into this Agreement, along with
LLC, to establish the Parties’ rights and obligations regarding certain know-how, inventions and patent rights; 
 NOW,
THEREFORE, in consideration of the mutual covenants set forth herein, the Parties agree as follows: 
 ARTICLE 1 -
DEFINITIONS 
 1.1 Capitalized terms that are not otherwise defined herein shall have the meanings given those
respective terms in the LLC Agreement. 
 1.2 “Confidential Information” shall have the meaning as set forth in
the Master Confidentiality Agreement. 
 *Confidential Treatment Requested 

  
 1 

 1.3 The following terms shall have the meanings set forth below: 

“Additive” shall mean the additive set forth in Schedule A. 

“Application” means any use of an LLC Product or any method for using an LLC Product. 

“BioAmber Collaboration Patent Rights” means Patent Rights owned or controlled by BioAmber claiming all or any part of
BioAmber Collaboration Technology. 
 “Sinoven Background Patent Rights” means the Patent Rights set forth in
Schedule A, and any Patent Rights owned or controlled by Sinoven as may be identified by Sinoven pursuant to Section 2.1 of the Research Services Agreement. 
 “Sinoven Background Technology” means the Technology relating to the use of the Additive in conjunction with PBS or LLC Products, as described in Schedule A. 

“Sinoven Collaboration Patent Rights” means Patent Rights owned or controlled by Sinoven claiming all or any part of
Sinoven Collaboration Technology. 
 “Collaboration Technology” of a Party (other than LLC) means Foreground
Technology (other than Research Technology) owned by a Party other than LLC pursuant to Section 2.2 hereof, that is (1) a Recipe, (2) Technology specifically pertaining to a use or methods of using of LLC Products, or
(3) Technology specifically pertaining to methods of making LLC Products (but not to methods for making any ingredients of LLC Products, including without limitation PLA, PBS or Sinoven Modified PBS), and that is conceived by at least one
employee, agent or contractor of such Party after the Effective Date but prior to the earlier of (i) the first anniversary of the Transfer by such Party (or in the case of BioAmber, the Transfer by Sinoven) of its Membership Interest (other
than to an Affiliate), and (ii) the dissolution of LLC. 
 “Exploit” and cognates thereof, means:
(a) with respect to a Patent Right, making, having made, using, selling, offering for sale, importing, or exporting an invention claimed in such Patent Right, or granting license rights under such Patent Right to do any of the foregoing; and
(b) with respect to Technology, using or transferring the Technology or part thereof in conjunction with the making, having made, using, selling, offering for sale, importing, or exporting of a product or method, or granting license rights
under such Technology to do any of the foregoing. 

  

*Confidential Treatment Requested 
  

2 

 “Field” means the research and development, manufacture, sale and use of
LLC Products. 
 “Foreground Patent Rights” shall mean any Patent Right claiming all or any part of Foreground
Technology. 
 “Foreground Technology” shall mean Technology, including any Recipes, conceived after the
Effective Date by one or more employees, agents or contractors of any one of the Parties, or jointly by at least one employee, agent or contractor of one Party with at least one employee, agent or contractor of at least one other Party. 

“LLC” shall mean that limited liability corporation formed and jointly owned by NatureWorks and Sinoven (directly or
indirectly) pursuant to the LLC Agreement. 
 “LLC Agreement” shall mean the agreement of even date herewith
among NatureWorks, Sinoven and LLC for the organization, operations and management of LLC, as the same may be amended from time to time. 
 “LLC Technology” means Foreground Technology owned by LLC pursuant to Article II, including without limitation Research Technology. 

“LLC Patent Rights” means Patent Rights owned by LLC pursuant to Article II, including without limitation Research
Patent Rights. 
 “Master Confidentiality Agreement” shall mean Master Confidentiality of even date herewith
among NatureWorks, Sinoven, BioAmber Inc. and LLC, as the same may be amended from time to time. 
 “NatureWorks
Background Patents Rights” shall mean the Patent Rights set forth in Schedule B, and any Patent Rights owned or controlled by NatureWorks as may be identified by NatureWorks pursuant to Section 2.1 of the Research Services Agreement.

 “NatureWorks Collaboration Patent Rights” means Patent Rights owned or controlled by NatureWorks claiming
all or any part of the NatureWorks Collaboration Technology. 
 “Net Revenues” means the gross revenues
received by NatureWorks and its Subsidiaries for the sale of LLC Products, net of any of the following items, to the extent paid or incurred by NatureWorks or its Subsidiaries: (i) all taxes paid with respect to such LLC Products (other than
taxes on income), (ii) interest and other finance charges, (iii) customs duties, surcharges and other governmental charges, (iv) freight, postage, transportation, insurance, packing and storage and warehousing charges incurred with
unaffiliated entities, and (v) refunds, returns, credits, 

  

*Confidential Treatment Requested 
  

3 

 
discounts, and allowancesactually paid, incurred or given, provided that such refunds, returns, credits, discounts and allowances are not inconsistent with any written policy approved by Sinoven
or are otherwise agreed to in writing by Sinoven. 
 “Non-LLC Products” means products other than LLC Products,
including without limitation Modified PBS Products. 
 “Patent Rights” means (a) the claim(s) of any
patent application filed in any country; (b) the claim(s) of all Letters Patent including supplemental protection certificates that have issued or may in the future issue including, without limitation, utility models, design patents, and
certificates of invention; and (c) the claim(s) of all divisionals, continuations, continuations-in-part, reissues, re-examination certificates, renewals, extensions, or additions to any such Letters Patent and patent applications. 

“Party” shall mean one of the parties to this Agreement; Parties shall mean all of the parties to this Agreement.

 “Related Party,” of any Party, for the purpose of this Agreement, means any other Entity at least percent
(25%) of the total voting securities of every class or other evidences of ownership interest of which is directly or indirectly owned or controlled by such Party. For purposes of this Technology License Agreement, LLC is not a Related Party of
Sinoven, BioAmber or NatureWorks. 
 “Recipe” shall mean a formulation for an LLC Product, including a listing
of all ingredients and the operable ranges concentrations and/or ratios of each such ingredient in the formulation. 

“Research Services Agreement” shall mean each agreement of even date herewith between LLC and either of NatureWorks and
Sinoven for the provision of certain research services by each such Party to LLC, as the same may be amended from time to time. 

“Research Technology” means any Technology conceived under a Research Agreement. 

“Research Patent Rights” means any and all Patent Rights claiming all or any part of Research Technology. 

“Seconding Agreement” means that certain Seconding Agreement of even date herewith between BioAmber Inc. and LLC
whereby certain employees of BioAmber Inc. are seconded to the LLC, as the same may be amended from time to time. 

“Sinoven Modified PBS” means PBS modified by the incorporation of the Additive. 

  

*Confidential Treatment Requested 
  

4 

 “Sinoven Modified PBS Products” means any product made with or
incorporating Sinoven Modified PBS. 
 “Sole Foreground Technology” of a Party means Foreground Technology
solely owned by that Party pursuant to Article II. 
 “Technology” means any discovery, development or
invention (including without limitation any Recipe) whether or not patentable, or susceptible to any other form of legal protection. 
 “Third Party” means any Entity that is not Sinoven, BioAmber Inc. or NatureWorks, or LLC. 
 ARTICLE II – OWNERSHIP AND DISCLOSURE OF TECHNOLOGY 
 2.1. Each
of BioAmber, Sinoven and NatureWorks will retain ownership of all Technology and Patent Rights owned by such Party as of the Effective Date, including without limitation, as to each Member, the respective Members’ Background Technology and
Background Patent Rights. 
 2.2 Except as provided in Section 2.4, each Party will own all right, title, and interest in
and to any Foreground Technology conceived by one or more employees, agents or contractors of such Party, either solely or jointly with one or more Third Parties, and all Patent Rights claiming all or any part of such Foreground Technology.

 2.3 Except as provided in Section 2.4, Foreground Technology conceived jointly by at least one employee, agent or
contractor of a Party other than LLC and at least one employee, agent or contractor of LLC, and any Patent Rights claiming all or any part of such Foreground Technology, shall be solely owned by LLC if and to the extent such Foreground Technology
relates to LLC Products, and shall be solely owned by such Party other than the LLC if and to the extent such Foreground Technology relates to Non-LLC Products. 
 2.4 Notwithstanding Sections 2.2 and 2.3, LLC shall own all Research Technology and Research Patent Rights, and any technical data generated pursuant to any research services provided to LLC pursuant to a
Research Services Agreement. 
  

  

*Confidential Treatment Requested 
  

5 

 2.5 For purposes of this Agreement, a contractor, employee or agent of BioAmber or Sinoven
who is seconded to LLC pursuant to the Seconding Agreement is deemed to be a contractor, employee or agent of LLC while so seconded, for the sole purpose of determining ownership of Technology or Patent Rights under this Agreement, including
Sections 2.2 and 2.3 hereof. 
 2.6 Notwithstanding this Article II, and subject to the terms and conditions of the LLC
Agreement, the Parties may otherwise decide in writing the ownership of any Foreground Technology or Foreground Patent Rights between or among them and/or the LLC. 
 2.7 Each Member and BioAmber may freely Exploit any Technology and Patent Rights solely owned by such Party, without the consent of or accounting to the other Parties, subject to the terms and conditions
of this Agreement, the Master Confidentiality Agreement and the LLC Agreement, including without limitation the provisions of Article XV of the LLC Agreement. The LLC may Exploit any Technology and Patent Rights owned by the LLC, or licensed to the
LLC hereunder or by any Third Party, only for the Business Purpose, or as otherwise permitted in writing by the Governance Board, subject to the terms and conditions of this Agreement, the Master Confidentiality Agreement and the LLC Agreement.

 2.8 Disclosures of Technology and Patent Rights 
 (a) Each Member shall disclose all Research Technology and, to the extent such disclosure does not require the consent of any Third Party (other than a Subsidiary of such Member), each Party shall
disclose all of that Party’s Collaboration Technology to the other Parties. If such Collaboration Technology is of a general nature and is applicable to both LLC Products and Non-LLC products, the Member or BioAmber, as the case may be, shall
advise LLC and the other Parties that such Collaboration Technology forms part of Technology of a general nature. LLC shall disclose all LLC Technology to each of the Members. 

(b) All Recipes disclosed by Sinoven as Sinoven Background Technology or required to be disclosed by either Member or BioAmber pursuant
to Section 2.8 (a) hereof will include instructions, to the extent known by the disclosing Party, for making and using that Recipe. 
 (c) Each Member and BioAmber shall provide an updated list of their respective Background Patent Rights (if a Member) and Collaboration Patent Rights (to the extent such disclosure does not require the
consent of any Third Party (other an a Subsidiary of such Member or of BioAmber)) to the other Parties, and LLC will provide an updated list of any LLC Patent Rights to each Member. 

  

*Confidential Treatment Requested 
  

6 

 (d) Disclosures and updated lists made in accordance with paragraphs (a) and
(c) of this Section 2.8 will be made in writing at least once each calendar quarter, promptly upon request by either Member or the LLC, or as otherwise agreed by the Governance Board. LLC shall maintain a written inventory of all of the
foregoing disclosures of Technology and lists of Patent Rights. 
 2.9 Notwithstanding any other provision of this Agreement, no
Party shall be required to license, disclose or transfer any Patent Rights or Technology under this Agreement that cannot be disclosed, licensed or transferred without the consent of Third Parties (other than Subsidiaries of such Party or BioAmber).

 2.10 Each Party shall upon request of another Party execute and deliver one or more written assignments of any Technology and
Patent Rights as may be necessary to effect the provisions of this Article II and/or permit the owning Party to record its ownership interest therein. 
 ARTICLE III – LICENSE GRANTS TO AND FROM LLC 
 3.1 Sinoven
hereby grants to LLC a worldwide, non-exclusive license under the Sinoven Background Technology and the Sinoven Background Patent Rights, solely to the extent necessary to make, have made, use, sell, offer for sale, export and import LLC Products
for the Business Purpose. Subject to the terms and conditions hereof, for such period as Sinoven owns a Membership Interest in LLC, LLC will pay Sinoven a running royalty of seven percent (7%) of Net Revenues from sales by NatureWorks and its
Subsidiaries of LLC Products, in consideration of the license granted under this Section 3.1. The annual royalty payable with respect to any calendar year shall be paid to Sinoven by January 31 of the succeeding calendar year. The first
such annual royalty shall become due on January 31, 2013 (for the period from the inception of the LLC until December 31, 2012). If Sinoven Transfers its Membership Interest (other than to an Affiliate of Sinoven), the license granted
under this Section 3.1 shall thereafter be fully paid-up and royalty-free. 
 3.2 NatureWorks hereby grants to LLC a
worldwide, non-exclusive, royalty-free license under the NatureWorks Background Patent Rights solely to the extent necessary to make, 

  

*Confidential Treatment Requested 
  

7 

 
have made, use, sell, offer for sale, export and import LLC Products for the Business Purpose, provided that any right granted under the [***] Patents (as defined in Section 7.3 of this
Agreement) solely applies to the use of LLC Products to the extent they contain PLA purchased from NatureWorks. 
 3.3 Each
Member and BioAmber hereby grants to LLC a worldwide, non-exclusive, royalty-free license under its respective Collaboration Technology and Collaboration Patent Rights solely to the extent necessary to make, have made, use, sell, offer for sale,
export and import LLC Products for the Business Purpose. 
 3.4 The licenses granted under Sections 3.1, 3.2 and 3.3 shall be
non-transferrable, except as permitted under Article IX hereof. 
 3.5 (a) LLC shall have the right to grant sublicenses under
the licenses granted to it under Sections 3.1, 3.2 and 3.3 hereof only (1) to Subsidiaries of LLC, (2) in accordance with Section 10.3(a) hereof, in the event of a Transfer by a Member of its Membership Interest, to the remaining
Member, or (3) solely to the extent the Technology or Patent Rights licensed under such sections pertain to or claim any Application, to any direct or indirect purchaser or transferee of LLC Products or downstream products made from or with LLC
Products. 
 (b) The purchase by NatureWorks of any LLC Products from LLC shall include a royalty-free license under the Sinoven
Background Patent Rights, the Sinoven Collaboration Patent Rights, the BioAmber Collaboration Patent Rights and LLC Patent Rights solely to the extent necessary to use the LLC Product so sold or transferred in any Application, which license shall be
transferrable with the further sale or transfer of such LLC Products by NatureWorks or its Subsidiaries. 
 3.6 Either Member,
while it owns a Membership Interest in LLC, including immediately prior to the Transfer of its Membership Interest or immediately prior to dissolution of LLC, shall have the right to obtain a license from LLC under any or all of LLC Technology and
LLC Patent Rights to make, have made, use, offer to sell, sell, export and import Non-LLC Products other than Sinoven Modified PBS and Sinoven Modified PBS Products. 
 (a) A license granted under this Section 3.6 shall be royalty-free, non-exclusive, worldwide, and transferrable only with the sale or transfer of that portion of the requesting Member’s business
to which this Agreement pertains. 
 (b) A license granted under this Section 3.6 shall permit the licensed Member to grant
sublicenses to any Third Party. 

  

*Confidential Treatment Requested 
  

8 

 (c) No license granted under this Section 3.6 shall extend to any LLC Technology
conceived after the effective date of the Transfer of the requesting Member’s Membership Interest, or any Patent Rights claiming all or any part of any such LLC Technology. 

3.7 All licenses granted under this Article III are subject to the terms and conditions of this Agreement, the Master Confidentiality
Agreement and the LLC Agreement, including without limitation Article XV of the LLC Agreement. 
 ARTICLE IV
–CONFIDENTIALITY, PROHIBITED RESEARCH AGREEMENTS 
 4.1 All non-public proprietary Technology shall be considered
to be the Confidential Information of the owning Party. Except as expressly permitted herein, each Party will treat the non-public proprietary Technology of each other Party in accordance with the terms and conditions of the Master Confidentiality
Agreement. 
 4.2 Without the prior written consent of the other Member, while each Member (or an Affiliate of such Member) owns
a Membership Interest in LLC and for one year after such Member Transfers its Membership Interest in LLC (other than to an Affiliate), such Member will not, and will cause its Subsidiaries not to, enter into any agreement with any Third Party (which
is not a Subsidiary of such Member) to perform research and/or development to develop Recipes for LLC Products unless such agreement permits such Member or Subsidiary to disclose and license any such Recipes to LLC as that Member’s
Collaboration Technology as provided in Article III hereof. Without the prior written consent of NatureWorks, until the merger of Sinoven into BioAmber, BioAmber will not, and will cause its Subsidiaries not to, enter into any agreement with any
Third Party (which is not a Subsidiary of BioAmber) to perform research and/or development to develop Recipes for LLC Products unless such agreement permits BioAmber or such Subsidiary to disclose and license any such Recipes to LLC as
BioAmber’s Collaboration Technology as provided in Article III hereof. However, nothing in this Section 4.2 will prohibit any Member or BioAmber from entering into nondisclosure agreements with any of its direct or indirect customers or
from providing technical service to any of its direct or indirect customers. 

  

*Confidential Treatment Requested 
  

9 

 ARTICLE V - PATENT PROTECTION 

5.1 Each Party shall have the right, in its sole discretion, to file one or more patent applications claiming its Sole Foreground
Technology. Any such application and Patent Rights deriving therefrom shall be owned by such Party. If a Member or BioAmber decides not to file a patent application claiming all or any part of its Collaboration Technology, it shall inform the other
Parties, and the LLC may at its own expense file prosecute issue or maintain such patent application(s); however, in that event such Member or BioAmber, as the case may be, will continue to own such Collaboration Technology and the Patent Rights
claiming all or any part of such Collaboration Technology. 
 5.2 If requested to do so, the other Parties shall provide any
reasonable assistance requested by the filing Party for the preparation, filing and prosecution of any patent applications entitled to be filed by such Party under this Agreement, and the enforcement of any patents that may issue therefrom,
including the execution of inventorship declarations, assignment deeds, and affidavits, participation in examiner interviews, and providing deposition and trial testimony where needed, but not including the payment of any attorney’s fees,
expenses or other costs associated with the preparation, prosecution or issuance of any Patent Right or any litigation. The filing Party shall reimburse the Party(s) providing such assistance for their reasonable out-of-pocket expenses incurred by
them under this Section 5.2. 
 5.3 Should a Party elect not to prosecute or maintain any of its Patents Rights which such
Party has licensed or is obligated to license to another Party hereunder, then it shall provide timely notice to the other Parties, who shall then have the secondary right to prosecute and maintain such Patent(s) at their own cost. Such Patent
Rights shall, however, continue to be owned by the original owning Party and not by the Party electing to prosecute or maintain the Patent(s). 
 5.4 Coordination of Patent Filings 
 (a) Before filing any patent application
claiming all or any part of Research Technology or any jointed conceived Foreground Technology which it owns pursuant to Section 2.3 hereof, LLC will inform the Party that performed the corresponding Research Services or jointly conceived the
Foreground Technology and will at the request of such Party coordinate the filing of such patent applications with such Party. 

  

*Confidential Treatment Requested 
  

10 

 (b) Before filing any patent application claiming all or any part of any jointed conceived
Foreground Technology which it owns pursuant to Section 2.3 hereof, a Party that jointly conceived the Foreground Technology will at the request of LLC coordinate the filing of such patent applications with the LLC. 

ARTICLE VI - PATENT/TRADE SECRET ENFORCEMENT 
 6.1 Each Party will have the exclusive right, but not the obligation, at its sole expense, to enforce its respective Patent Rights or other intellectual property rights outside the Field. The other
Parties have no obligation to cooperate in or contribute to any such enforcement and will have no right to share in any recovery. The Party bringing any such enforcement action shall keep all proceeds recovered from such legal proceeding.

 6.2 Each Party will promptly notify the other Parties in writing if it learns of any actual, alleged or threatened
infringement of any Background Patent Right, LLC Patent Right, Collaboration Patent Right or other intellectual property right with respect to any Background Technology, LLC Technology or Collaboration Technology by a Third Party in the Field,
unless such Party is not permitted to do so because of an obligation of non-disclosure to such Third Party (other than a to a Subsidiary of such Party, or in the case of Sinoven, to an Affiliate). The Party owning or controlling the affected Patent
Right or other intellectual property right (the “Controlling Party”) will have the first right, but not the obligation, at its own expense, to bring suit (or take other appropriate legal action) against any such actual, alleged, or
threatened infringement of the Patent Right or other intellectual property right, including the defense and settlement. In such a case, the Controlling Party shall keep all proceeds recovered from such legal proceeding. If the Controlling Party is a
Member, and does not initiate an infringement action or otherwise take affirmative measures to abate any such actual, alleged, or threatened Third-Party infringement within ninety (90) days after receiving the written notice of the
infringement, then the LLC will have the right, but not the obligation, at its own expense and upon written consent of all Members (which each Member may withhold in its sole and absolute discretion), to bring suit (or take other appropriate legal
action) against such Third Party(ies) 

  

*Confidential Treatment Requested 
  

11 

 
with respect to such actual, alleged, or threatened infringement, including the defense and settlement thereof. In the event any Party brings an infringement action in accordance with this
Section 6.2, such Party will notify the other Parties in writing at least fifteen (15) days prior to filing such action and the other Parties will provide reasonable assistance and authority to file and bring the action, including, if
required to bring such action, being joined as a party plaintiff; provided, however, that no Party will be required to transfer any right, title, or interest in or to any of its Patent Rights or Technology to any other Party to confer standing on a
Party hereunder. In addition, if any Party brings an infringement action hereunder, the other Parties will have the right to be represented separately in such action by counsel of its own choice, at its own expense. Any recovery realized as a result
of such suit, claim, or action or related settlement will first be applied pro rata to reimburse the Parties’ reasonable costs and expenses in connection with such suit, claim, or action. Any recovery remaining after such application shall be
allocated as mutually agreed by the Party bringing such enforcement action and the Party which owns the Patent Right or Technology that was the subject of such enforcement action. 

6.3 Notwithstanding the other provisions of this Article VI, LLC may enforce its intellectual property rights or those of another Party
as provided in Paragraph 6.2 only with the prior written consent of all Members (which consent may be withheld by each Member in its sole and absolute discretion). 
 ARTICLE VII – WARRANTY 
 7.1 Express Warranties of Each Member

 (a) Sinoven, NatureWorks and BioAmber each represents and warrants that, as of the Effective Date, it has the right to grant
any licenses that it provides, pursuant to Article III, and to disclose any Confidential Information that it discloses, pursuant to Article II and that it has not made and will not make any commitments to others inconsistent with or in derogation of
such rights. 
 (b) Sinoven, BioAmber and NatureWorks each represents and warrants that, as of the Effective Date, it and its
Subsidiaries own or control no Patent Rights other than those listed in Schedule A (as to Sinoven and BioAmber) and Schedule B (as to NatureWorks) that claim any Recipe listed in Schedule A hereto, or method of making or using such Recipe.

  

*Confidential Treatment Requested 
  

12 

 7.2 In addition, Sinoven and BioAmber make the following additional representations and
warranties, as of the Effective Date, with respect to the Sinoven Background Technology and Sinoven Background Patent Rights: (i) Sinoven is the sole, absolute and exclusive owner of the Sinoven Background Technology and the Sinoven Patent
Rights; (ii) as of the Effective Date, neither Sinoven nor BioAmber has received any written notice of a pending or threatened claim or litigation to which Sinoven or BioAmber is a party contesting the ownership, derivation, inventorship,
validity or right to use any of the Sinoven Background Technology or Background Patent Rights; and (iii) there are no Patent Rights or other rights, other than the Background Patent Rights, which are owned or controlled by Sinoven, BioAmber or
their respective Subsidiaries that are reasonably necessary for the Exploitation of LLC Products. 
 7.3 In addition,
NatureWorks makes the following additional representations and warranties, as of the Effective Date, with respect to the NatureWorks Background Patent Rights: (i) NatureWorks is the sole, absolute and exclusive owner of US Patent No. [***], US
Patent No. [***], Japanese Patent No. [***] and European Patent No. [***]; (ii) NatureWorks is a licensee under United States Patent No. [***], Japanese Patent No. [***] and European Patent No. [***] (collectively, the “[***]
Patents”) and has the right to grant sublicenses thereunder as provided herein, (iii) as of the Effective Date, NatureWorks has not received any written notice of a pending or threatened claim or litigation to which NatureWorks is a
party contesting the ownership, derivation, inventorship, validity or right to use any of the NatureWorks Background Patent Rights, and (iv) there are no Patent Rights or other rights, other than the NatureWorks Background Patent Rights, which
are owned or controlled by NatureWorks or its Subsidiaries that are reasonably necessary for the Exploitation of LLC Products. 

7.4 AS A LICENSOR, EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 7.1, 7.2 OR 7.3, EACH PARTY MAKES NO WARRANTIES OF ANY MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, PATENT VALIDITY, PATENT ENFORCEABILITY, OR ANY OTHER EXPRESS OR IMPLIED WARRANTY REGARDING ITS TECHNOLOGY, PATENT RIGHTS OR CONFIDENTIAL INFORMATION. ALL SUCH WARRANTIES ARE HEREBY DISCLAIMED.

  

*Confidential Treatment Requested 
  

13 

 ARTICLE VIII - INDEMNIFICATION 

8.1 Except to the extent the one or more of the other Parties is required to provide indemnity to a Party pursuant to Section 8.2
hereof, each Party shall indemnify, defend, and hold harmless the other Parties from any and all demands, claims, causes of action, damages, costs, and expenses (including reasonable attorneys and expert witness fees), arising out of, resulting
from, or related to that Party’s own actions, including without limitation exploitation of the license rights granted to it under this Agreement, including patent infringement actions. 

8.2 Each Party agrees to defend, indemnify, and hold harmless the other Parties, their Affiliates, and their respective, officers,
directors, employees, and agents, (each, an “Indemnified Party”) from and against any claims, demands, suits or causes of action, and judgments, damages, costs and expenses (including reasonable attorneys’ fees) resulting therefrom,
related to any breach of the representations and warranties made by such Party in Sections 7.1, 7.2 and 7.3 hereof; provided that Indemnified Party provides the indemnifying Party with (i) prompt written notice of such claim or action,
(ii) the opportunity to control the defense or settlement of such claim or action, and (iii) reasonable information and assistance in the defense and/or settlement any such claim or action. 

8.3 NatureWorks agrees to defend, indemnify, and hold harmless the other Parties, their Affiliates, and their respective officers,
directors, employees, and agents, (each, an “Indemnified Party”) from and against any claims, demands, suits or causes of action, and judgments, damages, costs and expenses (including reasonable attorneys’ fees) resulting therefrom,
related to any claim of infringement of United States Patent No. [***] arising out of the sale of LLC Products by LLC to NatureWorks; provided that the Indemnified Party provides NatureWorks with (i) prompt written notice of such claim or
action, (ii) the opportunity to control the defense or settlement of such claim or action, and (iii) reasonable information and assistance in the defense and/or settlement any such claim or action. 

ARTICLE IX - TERM AND TERMINATION 
 9.1 This Agreement shall be effective as of the Effective Date and shall terminate upon the dissolution of LLC. A Party’s obligations pursuant to Articles IV, VI, VII and VIII of this Agreement,
shall survive termination of this Agreement. 

  

*Confidential Treatment Requested 
  

14 

 9.2 Upon dissolution of LLC by Sinoven and NatureWorks: 

(a) All license rights provided to the LLC by NatureWorks, Sinoven and/or BioAmber shall terminate; 

(b) The ownership of LLC Technology and all intellectual property rights owned by LLC, including without limitation LLC Patent Rights,
trademarks, copyrights and trade secret rights, shall be vested equally and jointly in Sinoven and NatureWorks. Sinoven and NatureWorks each may freely Exploit such LLC Technology and intellectual property rights formerly owned by the LLC without
the consent of or accounting to the other; and 
 (c) Any trademark license granted to LLC pursuant to Article 11 shall
terminate. 
 9.3 In the event either Sinoven or NatureWorks (or both of them) (“Transferring Member”) Transfer its
respective entire Membership Interest in the LLC to any Entity(s) other than an Affiliate of the Transferring Member, then: 

(a) All license rights provided to LLC by the Transferring Member or by BioAmber (if Sinoven is the Transferring Member) pursuant to
Section 3.1, 3.2, and 3.3 remain in effect, and may be transferred or sublicensed by LLC to the remaining Member, provided that if the Transferring Member is Sinoven any license under Section 3.1 that is transferred or sublicensed to
NatureWorks under this Section 9.3(a) shall be fully paid-up and royalty-free; and 
 (b) All license rights provided to
the Transferring Member by the LLC pursuant to Section 3.6 remain in effect. 
 ARTICLE X-LICENSES BETWEEN MEMBERS
UPON DISSOLUTION OR 
 TRANSFER OF A MEMBER’S MEMBERSHIP INTEREST 

10.1 (a) Upon (i) any dissolution of LLC by Sinoven and NatureWorks or (ii) upon the Transfer of either Member’s
Membership Interest (other than to an Affiliate) and if NatureWorks Transfers its Membership Interest, the expiration of the applicable period specified in Section 15.1(c) of the LLC Agreement, NatureWorks shall have the right to obtain a
license from Sinoven under any or all of the Sinoven Background Technology and Sinoven Background Patent Rights solely to the extent necessary to make, have made, use, offer to sell, sell, export and import LLC Products. 

  

*Confidential Treatment Requested 
  

15 

 (b) The license granted under this Section 10.1 shall be royalty-bearing as follows:

 (1) NatureWorks shall pay Sinoven a royalty equal to five percent (5%) of the Net Revenues from sales by NatureWorks or its
sublicensees of LLC Products that contain Sinoven Modified PBS, multiplied by the percentage by weight of Sinoven Modified PBS in such LLC Products. 
 (2) The license granted under this Section 10.1 shall be royalty-free with respect to LLC Products that do not contain the Sinoven Modified PBS. 

(3) Nothing in this Agreement shall be construed as (i) preventing NatureWorks or its sublicensees from making any use of the
Recipes, in whole or in part, (including the Additive described therein), other than in connection with LLC Products or PBS or (ii) requiring NatureWorks to pay royalties to Sinoven hereunder for any use of the Additive other than in connection
with LLC Products. 
 (4) To the extent NatureWorks pays a royalty to Sinoven under this Section 10.1 with respect to any
specific quantity of Sinoven Modified PBS contained in an LLC Product, NatureWorks shall not be required to pay any additional royalty with respect to the use of that specific quantity of Sinoven Modified PBS by NatureWorks, its sublicensees or any
other Third Party to make LLC Products. 
 (5) Notwithstanding any other provision of this Agreement, the obligation to pay
further royalties under this Section 10.1 will cease upon the first to occur of (i) the seventh anniversary of this Technology License Agreement, (ii) the payment by NatureWorks of aggregate royalties of five million dollars
($5,000,000.00) under this Section 10.1 and (iii) the date upon which the Sinoven Background Technology (A) becomes part of the public domain through no unauthorized act of NatureWorks, its Subsidiaries, agents, contractors or
sublicensees, or (B) is independently developed by any party other than NatureWorks, its Affiliates, agents or contractors. 
 10.2 Upon any dissolution of LLC by Sinoven and NatureWorks or upon the Transfer of either Member’s Membership Interest (other than to an Affiliate), Sinoven shall have the right to obtain a license
from NatureWorks under any or all of the NatureWorks Background Patent Rights solely to the extent necessary to make, have made, use, offer to sell, sell, export and import LLC Products, provided that any such license under the [***] Patents shall
be granted only to the extent such LLC Products include PLA purchased from NatureWorks. 

  

*Confidential Treatment Requested 
  

16 

 (a) Subject to the payment of the royalty specified in Section 10.2(b) and, in the
event of a Transfer by Sinoven’s Membership Interest, after the applicable period specified in Section 15.1(c) of the LLC Agreement, Sinoven shall have the the right to grant sublicenses under the NatureWorks Background Patent Rights to
any Third Party with the sale or transfer of any product by Sinoven or its Affiliates solely with respect to the use of such sold or transferred product. 
 (b) Sinoven shall pay NatureWorks a reasonable royalty to be negotiated by Sinoven and NatureWorks with respect to LLC Products made by Sinoven or its sublicensees under this Section 10.2 under the
NatureWorks Background Patent Rights. Notwithstanding the foregoing, the obligation to pay further royalties under this Section 10.2 will cease upon the first to occur of (i) the seventh anniversary of this Technology License Agreement and
(ii) the payment by Sinoven of aggregate royalties of five million dollars ($5,000,000) under this Section 10.2. 

10.3 (a) Upon any dissolution of LLC by Sinoven and NatureWorks, (i) Sinoven shall have the right to obtain a royalty-free license
from NatureWorks under any or all of NatureWorks’ Collaboration Technology and NatureWorks’ Collaboration Patent Rights solely to the extent necessary to make, have made, use, offer to sell, sell, export and import LLC Products and
(ii) NatureWorks shall have the right to obtain a royalty-free license from Sinoven under Sinoven’s Collaboration Technology and Sinoven’s Collaboration Patent Rights and from BioAmber under BioAmber’s Collaboration Technology
and BioAmber’s Collaboration Patent Rights, in each case solely to the extent necessary to make, have made, use, offer to sell, sell, export and import LLC Products. 
 (b) Upon the Transfer of either Member’s Membership Interest (other than to an Affiliate of such Member), (i) Sinoven shall have the right to obtain a license from NatureWorks under any or all
of NatureWorks’ Collaboration Technology and Collaboration Patent Rights solely to the extent necessary make, have made, use, offer to sell, sell, export and import LLC Products and (ii) NatureWorks shall have the right to obtain a license
from Sinoven under Sinoven’s Collaboration Technology and Sinoven’s Collaboration Patent Rights and from BioAmber under BioAmber’s Collaboration Technology and BioAmber’s Collaboration Patent Rights, in each case solely to the
extent necessary to make, have made, use, offer to sell, sell, export and import LLC Products. In the event of such Transfer, the license under this Section 10.3(b) to the remaining Member shall be royalty free, and the license to the
Transferring 

  

*Confidential Treatment Requested 
  

17 

 
Member will bear a reasonable royalty to be negotiated by Sinoven or BioAmber, as the case may be, and NatureWorks with respect to LLC Products made pursuant to a license granted under this
Section 10.3(b). If NatureWorks and Sinoven or BioAmber, as the case may be, are unable to agree on a reasonable royalty, the royalty will be determined by an independent licensing expert mutually chosen by Sinoven and NatureWorks. 

(c) No license granted under this Section 10.3 shall extend to any Collaboration Technology conceived after the effective date of
any dissolution of LLC by Sinoven and NatureWorks. If either Member Transfers its Membership Interest (other than to any Affiliate of such Member), then any license granted to the Transferring Member under Section 10.3 hereof shall not include
any Collaboration Technology conceived after the effective date of such Transfer. 
 (d) Subject to the payment of the royalty
specified in Section 10.3(b) and, to the extent it is a Transferring Member, the expiration of the applicable period specified in Section 15.1(c) of the LLC Agreement, Sinoven and NatureWorks each shall have the right to grant sublicenses
under the other Member’s Collaboration Technology and Patent Rights (and/or BioAmber’s Collaboration Technology and Collaboration Patent rights, in the case of NatureWorks) to any Third Party with the sale or transfer of any product by
Sinoven or its sublicensees or NatureWorks or its sublicensees, as the case may be, solely with respect to the use of such sold or transferred product. 
 10.4 Any license granted under this Article X shall be non-exclusive, worldwide, and transferrable only with the sale or transfer of that portion of the licensee’s business to which this Agreement
relates. 
 10.5 A Member taking a license from the other Member (or from BioAmber, in the case of NatureWorks) under this
Article X shall have the right to grant sublicenses to its Related Parties, subject to the payment of royalties (to the extent such Member is not permitted to provide such sublicense on a royalty free basis) as provided in this Article X.

 10.6 Any license requested pursuant to this Article X shall be requested in writing within one year of the effective date of
dissolution of LLC by Sinoven and NatureWorks, or the Transfer of the of either of Sinoven’s or NatureWorks Membership Interest (other than to an Affiliate). 

  

*Confidential Treatment Requested 
  

18 

 10.7 Neither BioAmber nor a Member granting a license under this Article X
(“Licensor”) will assert against any Third Party, any claim for infringement of any Patent Rights licensed under such license, based on the manufacture, use, sale, offer for sale, or import of any product made or sold by the licensee or
any permitted sublicensee under such license, provided that if a royalty is due on any such product, such royalty is paid in accordance with the provisions hereof. 
 10.8 All licenses granted under this Article X (including any sublicenses granted hereunder) shall be subject to the obligations under Article XV of the LLC Agreement and the Master Confidentiality
Agreement. 
 10.9 Upon (i) any dissolution of LLC by Sinoven and NatureWorks or upon the Transfer of either Member’s
Membership Interest (other than to an Affiliate) and (ii) the expiration of the applicable period specified in Section 15.1(c) of the LLC Agreement, NatureWorks and Sinoven may enter into good faith negotiations for the conclusion of one
or other of a supply agreement, distribution agreement or license agreement allowing the use by NatureWorks of Sinoven Modified PBS in products other than LLC Products. 
 ARTICLE XI – CERTAIN TRADEMARK MATTERS 
 11.1 Sinoven and/or
BioAmber, at their sole expense, may conceive and develop a trademark for LLC Products and apply to register and register such trademark in any jurisdiction (each, a Sinoven Funded Trademark”). Any such Sinoven Funded Trademark, and any
goodwill pertaining thereto, shall be owned solely by Sinoven. Sinoven may offer a royalty-free license such trademark to LLC under such terms and conditions as may be agreed upon by the Governance Board, and upon taking such a license, LLC may sell
LLC Products under such trademark (as permitted in the Operative Agreements). LLC, with the advice and consent of the Governance Board, may permit direct or indirect purchasers of LLC Products from NatureWorks or LLC to re-sell such LLC Products
under such Sinoven Funded Trademarks under reasonable terms and conditions. 
 11.2 Upon dissolution of LLC by Sinoven and
NatureWorks, all right, title and interest in and to such Sinoven Funded Trademarks, including any goodwill pertaining thereto, shall remain owned solely by Sinoven. If requested by NatureWorks, Sinoven shall grant NatureWorks a worldwide, royalty
free license to use such trademarks in connection with the sale of LLC Products, for a period of one year after dissolution, subject to terms and conditions similar to those granted to LLC or NatureWorks prior to dissolution. 

  

*Confidential Treatment Requested 
  

19 

 11.3 If Sinoven Transfers its Membership Interest in LLC, any license granted under
the Sinoven Funded Trademarks to LLC, NatureWorks or any purchaser of LLC Products from NatureWorks or LLC shall remain in effect, subject to the same terms and conditions as existed immediately prior to such Transfer. In addition, in such case, if
such Transfer is other than to an Affiliate of Sinoven, LLC shall have the option to purchase from Sinoven all of its right, title and interest in and to the Sinoven Funded Trademarks at a price equal to one-half of the costs incurred by Sinoven in
prosecuting and maintaining such Sinoven Funded Trademarks prior to the date Sinoven transferred its Membership Interest.  
 ARTICLE XII - NOTICES 
 12.1 All communications, notices, consents
and other communications (collectively “Notices”) provided for in this Agreement or by law shall be in writing and be given by delivery (including personal delivery, delivery by courier, overnight delivery service, delivery by U.S.
certified mail, return receipt requested, or facsimile transmittal), with such Notices effective on receipt. Notices shall be addressed as follows: 
  

			
	if to LLC:	  	AmberWorks, LLC
		  	3850 Annapolis Lane North, Suite 180
		  	Plymouth, Minnesota, 55447
		  	Attention: General Manager
		  	Phone: [***]
		  	Fax: (763) 253-4499
		  	Email: [***]

 With a copy to Sinoven (if not sent by Sinoven) and to NatureWorks (if not sent by NatureWorks)

  

*Confidential Treatment Requested 
  

20 

			
	if to Sinoven at:	  	Sinoven Biopolymers Inc.
		  	3850 Annapolis Lane North, Suite 180
		  	Plymouth, Minnesota
		  	55447
		  	Attn: President & CEO
		  	Phone: (514) 844-8000 ext. [***]
		  	Fax: (514) 844-1414
		  	Email: [***]
		
	with a copy to:	  	Boivin Desbiens Senecal, g.p.
		  	2000 McGill College, Suite 2000
		  	Montreal, Quebec, Canada
		  	H3A 3H3
		  	Attn: Thomas Desbiens
		  	Phone: (514) 844-5468, ext. [***]
		  	Fax: (514) 844-5836
		  	Email: [***]
		
	if to NatureWorks at:	  	NatureWorks, LLC
		  	15305 Minnetonka Blvd.
		  	Minnetonka, MN 55345
		  	Attn: President
		  	Phone: [***]
		  	Fax: (952) 931-1466
		  	Email: [***]
		
	If to BioAmber, at:	  	BioAmber, Inc.
		  	3850 Annapolis Lane North
		  	Plymouth, Minnesota
		  	55447
		  	Attn: President & CEO
		  	Phone: (514) 844-8000 ext. [***]
		  	Fax: (514) 844-1414
		  	Email: [***]

 or at such other address as the LLC, Sinoven, NatureWorks or BioAmber may from time to time designate by Notice duly
given in accordance with the provisions hereof. 

  

*Confidential Treatment Requested 
  

21 

 ARTICLE XIII - DISPUTE RESOLUTION 

13.1 Dispute Resolution. The dispute resolution procedures and remedies set forth in Article XIV of the LLC Agreement will
be the sole and exclusive procedures and remedies for resolving any dispute or disagreement arising out of, or relating to, the formation, interpretation, performance or breach of this Agreement or any amendment hereto. If BioAmber is a party to
such a dispute or disagreement, the provisions of Article XIV shall apply mutatis mutandis to BioAmber. 
 ARTICLE XIV -
MISCELLANEOUS 
 14.1 Except as expressly set forth herein, no license or right is granted, by implication, estoppel or
otherwise, by any Party with respect to or under any patent, trade secret, copyright, technology, or other intellectual property or proprietary right of such Party. For the avoidance of doubt, notwithstanding any other provision of this Agreement,
in no event is any license or right granted by NatureWorks hereunder under any patent, trade secret, technology, or other intellectual property right to make lactic acid, lactide, any polymers or copolymer of lactic acid, lactide or any derivative
of lactic acid or lactide. 
 14.2 This Agreement, the LLC Agreement and the other Operative Agreements constitute the entire
agreement of the Parties relating to the subject matter of such Agreements, and supersede all prior contracts or agreements, whether oral or written, relating to such subject matter including the Memorandum of Understanding entered into between
BioAmber Inc. and Natureworks as of June 23rd 2011. There are no representations, warranties, agreements, arrangements or understandings, oral or written, between or among the Parties relating to the subject matter of the Operative Agreements
that are not fully expressed in the Operative Agreements. 
 14.3 For purposes of this Agreement, any copy, facsimile
telecommunication or other reliable reproduction of a writing, transmission or signature may be substituted or used in lieu of 

  

*Confidential Treatment Requested 
  

22 

 
the original writing, transmission or signature for any and all purposes for which the original writing, transmission or signature could be used; provided that such copy, facsimile
telecommunication or other reproduction shall be a complete reproduction of the entire original writing, transmission or signature, as the case may be. 
 14.4 Nothing in this Agreement, whether express or implied, shall be construed to give any Entity (other than the Parties and their permitted successors and assigns) any legal or equitable right,
remedy or claim under or in respect of this Agreement or any covenants, conditions or provisions contained herein, as a direct, indirect, intended or incidental third party beneficiary or otherwise. 

14.5 Each and all of the covenants, terms, provisions and agreements contained in this Agreement shall be binding upon and inure to the
benefit of the parties hereto and, to the extent permitted by this Agreement, their respective successors and assigns. 
 14.6
If any provision of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

14.7 The failure or delay on the part of any Party to exercise any of its respective rights hereunder upon the nonperformance by any
other Party of any term, condition, covenant or provision herein, shall not be construed as a waiver thereof nor shall the acceptance by one Party of the defective performance or a waiver of the non-performance of any such terms, conditions,
covenants or provisions on the part of any other Party be construed as a waiver of the rights of such Party with respect to such defective performance or nonperformance or as a waiver of the right of any Party as to any subsequent defective
performance or nonperformance thereof or of any other term, condition, covenant or provision hereof; nor shall any single or partial exercise of any rights by any Party preclude any other or further exercise thereof or the exercise of any other
right hereunder by any such Party or any other Party. No waiver or release of any of the terms, conditions, covenants or provisions of this Agreement shall be valid or effective unless the same is in writing duly executed by the Party to be bound
thereby. 
 14.8 This Agreement shall not be assigned by any Party except to a Transferee of such Party’s Membership
Interest in LLC permitted by the LLC Agreement. 
 14.9 Neither this Agreement nor any of the terms hereof may be
terminated, amended, supplemented or modified, except by an instrument in writing signed by all of the Parties. 

  

*Confidential Treatment Requested 
  

23 

 14.10 Article, Section, paragraph and other headings contained in this Agreement are for
reference purposes only and shall not be construed to define, interpret, limit or expand the scope, extent or intent of this Agreement or any provision hereof. 
 14.11 None of the Parties shall knowingly export or re-export any information or software received from the disclosing party, or the direct products of such information or software, to any country,
person, or entity, or for any use prohibited by the U.S. Export Administration Regulations, unless properly authorized by the U.S. Government. This assurance will be honored even after the expiration or termination of this Agreement. 

14.12 This Agreement may be executed in any number of counterparts with the same effect as if all signatory parties had signed the same
document. All counterparts shall be construed together and shall constitute one and the same instrument. 
 14.13 This
Agreement, and the application and interpretation hereof, shall be governed exclusively by and construed in accordance with its terms and by the internal laws of the State of Delaware, without reference to any conflict of law or choice of law
principles that the State of Delaware might apply the law of another jurisdiction. 

  

*Confidential Treatment Requested 
  

24 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed through their duly authorized and
empowered representatives as of the date set forth above. 
  

									
	NATUREWORKS, LLC	 		 	SINOVEN BIOPOLYMERS, INC.
					
	By:	 	 /s/ Marc Verbruggen
	 		 	By:	 	 /s/ Jean-François Huc

	Name:	 	Marc Verbruggen	 		 	Name:	 	Jean-François Huc
	Title:	 	President & CEO	 		 	Title:	 	Director
	Date:	 	February 15th, 2012	 		 	Date:	 	February 15th, 2012
			
	AMBERWORKS, LLC	 		 	BIOAMBER INC.
					
	By:	 	 /s/ Marc Verbruggen
	 		 	By:	 	 /s/ Jean-François Huc

	Name:	 	Marc Verbruggen	 		 	Name:	 	Jean-François Huc
	Title:	 	Duly authorized by the board	 		 	Title:	 	President & CEO
	Date:	 	February 15th, 2012	 		 	Date:	 	February 15th, 2012
					
	By:	 	 /s/ Jean-François Huc
	 		 		 	
	Name:	 	Jean-François Huc	 		 		 	
	Title:	 	Duly authorized by the board	 		 		 	
	Date:	 	February 15th, 2012	 		 		 	

 [Signature Page – Technology License Agreement] 

  

*Confidential Treatment Requested 
  

25 

 Schedule A: Sinoven Recipes , Sinoven Background Patents, and Additive

 [DISCLOSED SEPARATELY BY SINOVEN] 

  

*Confidential Treatment Requested 
  

26 

 Schedule B: Natureworks Background Patent Rights 

United States Patent No. [***] 
 United States
Patent No. [***] 
 European Patent No. [***] (registered in Belgium, France, Germany, Italy, Netherlands, United Kingdom) 

Japanese Patent No. [***] 
 US Patent No. [***]

 Japanese Patent No. [***] 
 European
Patent No. [***] 

  

*Confidential Treatment Requested 
  

27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]